Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Acquired by Hsbc Holdings PLC

Hsbc Holdings PLC grew its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 195.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,519 shares of the company’s stock after buying an additional 2,988 shares during the period. Hsbc Holdings PLC’s holdings in Krystal Biotech were worth $718,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Norges Bank bought a new stake in Krystal Biotech during the 4th quarter valued at $34,391,000. Raymond James Financial Inc. bought a new stake in shares of Krystal Biotech during the fourth quarter valued at about $15,989,000. Franklin Resources Inc. lifted its holdings in Krystal Biotech by 34.2% in the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock worth $43,774,000 after purchasing an additional 62,178 shares during the period. TimesSquare Capital Management LLC grew its position in Krystal Biotech by 39.1% in the 4th quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company’s stock valued at $24,888,000 after buying an additional 44,646 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Krystal Biotech by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company’s stock valued at $450,938,000 after buying an additional 28,707 shares during the period. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Down 2.3 %

Shares of NASDAQ:KRYS opened at $162.29 on Tuesday. The business has a 50 day moving average price of $174.63 and a 200 day moving average price of $171.10. The company has a market cap of $4.69 billion, a price-to-earnings ratio of 54.28 and a beta of 0.79. Krystal Biotech, Inc. has a twelve month low of $141.72 and a twelve month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company’s revenue for the quarter was up 116.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.30 EPS. Analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Analyst Ratings Changes

KRYS has been the subject of several recent analyst reports. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. HC Wainwright raised their target price on Krystal Biotech from $221.00 to $240.00 and gave the company a “buy” rating in a research note on Monday, April 28th. Chardan Capital boosted their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. Finally, Citigroup raised their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $222.71.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).